Aims: Major bleeding remains a major barrier to optimal anticoagulation in patients with atrial fibrillation (AF). We aimed to develop and externally validate a weighted score that balances clinical usability and predictive performance for 1-year major bleeding prediction. Methods and results: Using prospective multinational Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation (GLORIA-AF) Phase II/III data, we developed the GLORIA-AF Bleeding Weighted Risk Score using least absolute shrinkage and selection operator-penalized regression with stability selection, coefficient rescaling, and internal validation. The score was externally evaluated in EURObservational Research Programme Atrial Fibrillation and EURObservational Research Programme Atrial Fibrillation registries. Discrimination, calibration, and clinical benefit were assessed using concordance index (C-index), observed-to-expected ratio, calibration plot, and decision-curve analysis and compared with HAS-BLED, the unweighted GLORIA-AF score, and the full multivariable Cox model. Among 20 250 eligible derivation cohort patients [69.9 (10.3) years; 9092 female (44.9%)], 317 (1.6%) had major bleeding during 1-year follow-up. The derived score ranges from 0 to 22, with the highest weight (5) assigned to age >65 years, followed by abnormal kidney function (3). The derived score achieved a C-index of 0.688 (95% CI, 0.660–0.717), outperforming HAS-BLED (C-index, 0.631; 95% CI, 0.604–0.658; P < 0.001), while preserving discrimination comparable to full multivariable regression (C-index, 0.690; 95% CI, 0.661–0.719; P = 0.084). Calibration was good (observed-to-expected ratio, 0.996) and DCA showed a greater net benefit than HAS-BLED across 1–3% thresholds. Among 9752 external validation patients, 148 (1.5%) had major bleeding. The derived score achieved a C-index of 0.674 (95% CI, 0.643–0.705; P < 0.001), with better discrimination, calibration, and clinical benefit than HAS-BLED. Conclusion: The GLORIA-AF Bleeding Score showed modestly higher discrimination than HAS-BLED for 1-year major bleeding prediction while retaining clinical interpretability and usability. External validation in independent European and Asia-Pacific registries further supports its transportability beyond the derivation population.